Influencia del estado nutritivo y la enfermedad sobre las concentraciones de adiponectina y TNF-α en pacientes con cáncer colorrectal by Vicente, Mariana Abe et al.
140
Nutr Hosp. 2014;30(1):140-146
ISSN 0212-1611 • CODEN NUHOEQ
S.V.R. 318
Original / Cáncer
The influence of nutritional status and disease on adiponectin and TNF-α
levels in colorectal cancer patients
Mariana Abe Vicente1, Tiago Donizetti Silva2, Katia Barão3, Aledson Vitor Felipe4, Lila Oyama Missae5
and Nora Manoukian Forones6
1,2,3,4,6Departament of Medicine. Gastroenterology Division. Oncology Group. São Paulo. SP. Brazil. 5Departament of
Physiology. Physiology of Nutrition. São Paulo. SP. Brazil.
INFLUENCIA DEL ESTADO NUTRITIVO Y LA
ENFERMEDAD SOBRE LAS CONCENTRACIONES
DE ADIPONECTINA Y TNF-α EN PACIENTES
CON CÁNCER COLORRECTAL
Resumen
Antecedentes: El propósito de este estudio fue evaluar la
asociación entre las concentraciones séricas de adiponec-
tina y de factor de necrosis tumoral-α (TNF-α) en paciente
con cáncer colorrectal (CCR) y comparar estas concentra-
ciones con el estadio clínico y el estado nutritivo.
Métodos: Se reclutó a un total de 79 pacientes en el
estudio (39 con CCR y 40 en el grupo control). Se evaluó el
estado nutritivo mediante la Evaluación Global Subjetiva
Generada por el Paciente (PG-SGA), el índice de masa
corporal (IMC) y el ángulo de fase (AF). Se determinaron
las concentraciones séricas de adiponectina y de TNF-α
mediante un inmunoensayo de absorción ligado a enzima.
Resultados: Las concentraciones séricas de adiponec-
tina fueron superiores en los pacientes con CCR (p =
0,001). Las concentraciones séricas de TNF-α no fueron
significativamente distintas entre los grupos pero los
pacientes con CC en estadios III o IV tuvieron mayores
concentraciones de TNF-α que aquellos con un menor
estadio de la enfermedad (p = 0,037). Las tres herramien-
tas empleadas para evaluar el estado nutritivo (IMC, AF
y PG–SGA) demostraron que los pacientes con un déficit
nutricional más pronunciado presentaban mayores con-
centraciones de adipocitocina, aunque algunas diferen-
cias sólo fueron significativas para el TNF-α cuanto se
distribuyó el AF en terciles. 
Conclusiones: Las concentraciones de adiponectina
fueron superiores en pacientes con CCR. Aunque las con-
centraciones séricas de TNF-α de los pacientes con CCR
no diferían significativamente de las del grupo control, los
pacientes con CCR en estadios III o IV tuvieron concen-
traciones superiores en comparación con aquellos con
tumores en estadios I y II. El estado nutritivo, determi-
nado por IMC, AF y PG-SGA, demostró que los pacientes
con un mayor déficit nutricional tenían concentraciones
superiores de adipocitocinas; sin embargo, estas diferen-
cias sólo fueron significativas para el TNF-α cuando el AF
se distribuyó en terciles.
(Nutr Hosp. 2014;30:140-146)
DOI:10.3305/nh.2014.30.1.7132
Palabras clave: Adipocitocinas. Cáncer colorrectal  Eva-
luación nutricional.
Abstract
Background: The aim of this study was to evaluate the
association between adiponectin and tumor necrosis
factor-α (TNF-α) serum levels in colorectal cancer (CRC)
patients and compare these levels to clinical stage and
nutritional status.
Methods: A total of 79 patients were enrolled in the
study (39 with CRC and 40 in the control). Nutritional
status was assessed by Patient-Generated Subjective
Global Assessment (PG-SGA), body mass index (BMI),
and phase angle (PhA). Adiponectin and TNF-α serum
concentrations were determined using an enzyme-linked
immunosorbent assay.
Results: Serum adiponectin levels were higher among
CRC patients (p = 0.001). TNF-α serum levels were not
significantly different between the groups, but patients
with stage III or IV CRC had higher levels of TNF-α than
those with lower stage disease (p = 0.037). The three tools
used for the assessment of nutritional status (BMI, PhA,
and PG-SGA) demonstrated that patients with a more
severe nutritional deficit had higher adipocytokine levels,
although these differences were significant only to TNF-
α, when distributed PhA in tertiles. 
Conclusions: Adiponectin levels were higher among
CRC patients. Although TNF-α serum levels from CRC
patients did not differ significantly to the control group,
CRC patients with stage III or IV had higher levels
compared to those with stage I and II tumors. Nutritional
status, as determined by BMI, PhA, and PG-SGA,
demonstrated that patients with a greatest nutritional
deficit, had higher levels of adipocytokines; however,
these differences were significant only for TNF-α, when
distributed PhA in tertiles.
(Nutr Hosp. 2014;30:140-146)
DOI:10.3305/nh.2014.30.1.7132
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CRC: Colorectal cancer.
BMI: Body mass index.
PG-SGA: Patient-Generated Subjective Global As-
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SGA: Subjective Global Assessment.
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TNF-α: Tumor necrosis factor-α.
TNM: Tumor-node-metastasis.
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Introduction
Colorectal cancer (CRC) has a complex etiology that
includes the interaction of environmental and genetic
factors. Recent studies reported that obesity is associa -
ted with an increased risk of CRC, although the mecha-
nisms underlying this relationship remain to be fully
elucidated1. Such mechanisms, however, include dif-
ferent distributions of body fat, alterations in hormonal
status, obesity-related inflammation, and metabolic
disturbances2. In particular, the increased adipose tis-
sue in obesity causes an alteration of adipocytokine se-
cretion, which may influence cancer initiation and pro-
gression1,2. Furthermore, there is evidence that several
adipocytokines, (adiponectin, leptin, and TNF-α) have
the potential to mediate the relationship between adi-
posity and colorectal neoplasma3.
Tumor cells and tumor-associated leukocytes may
also produce inflammatory cytokines such as TNF-α4.
This cytokine has a possible role in all the steps in-
volved in cancer initiation and progression, including
cellular transformation, promotion, survival, prolifera-
tion, invasion, angiogenesis, and metastasis4,5. Addi-
tionally, TNF-α administration promptly lead to reduc-
tion of adiponectin expression and secretion6.
Adiponectin may in turn induce anti-angiogenesis and
anti-tumor activity6. Serum levels of adiponectin are
associated with the activation of apoptotic enzymes in
the caspase cascade, modulation of the expression of
several apoptosis related genes in myelomonocytic
cells, and reduction of tumor neovascularization4.
Food intake and energy homeostasis are regulated
by a complex network of peripheral mediators, inclu -
ding adipocytokines, changes in which can interfere
with nutritional status6. Several studies demonstrated
that adiponectin is inversely correlated with body
weight.7 and the decreased production of adiponectin in
obese subjects can stimulate cancer progression
through changes in insulin levels, inflammation, and
angiogenesis6-9. However, the relationship between
these cytokines or after weight loss in cancer patients
has not been clearly established7.
BMI, PhA, and PG-SGA are measures commonly
used to determine nutritional status. BMI, which is
easy to assess, has been the most widely used in epi-
demiological studies and clinical practice; however, it
is relatively insensitive for the diagnosis of undernutri-
tion10-12. PhA represents the electrical current stored by
cell membranes10, and its use has been studied in seve -
ral diseases, including cancer12,13. The PG-SGA14 is rec-
ommended as the standard method for the nutritional
assessment of cancer patients by the Oncology Nutri-
tion Dietetic Practice Group of the American Dietetic
Association15,16. It identifies symptoms commonly seen
during the treatment of cancer and includes a physical
examination for the subjective assessment of nutritio -
nal status16.
Some studies have demonstrated an association
among adiponectin and TNF-α serum levels, nutritio -
nal status, and clinicopathological variables in CRC
patients17, but these studies involved heterogeneous pa-
tient groups and lacked a control group7. The aim of
this study was to evaluate the association between
adiponectin and TNF-α serum levels in CRC patients
and determine if they are truly associated with the clini-
cal stage and nutritional status.
Patients and methods
Subjects
This cross-sectional study involved outpatients
treated by the Oncology Group from the Gastroentero -
logy Division of the Federal University of Sao Paulo,
between July 2010 and November 2011. The study was
approved by the local Ethics Committee (Protocol
0826/10), and all patients signed an informed consent
form. A total of 79 individuals were enrolled in the
study, 39 of whom were CRC patients –the case group
and 40 were healthy volunteers– the control group.
Data collection
Data on gender, age, treatment, site, and tumor stage
were obtained from the medical records. The nutritio -
nal evaluation and collection of the blood sample for
measuring adiponectin and TNF-α serum levels were
performed at the same time. All patients were classified
according to the tumor-node-metastasis (TNM) sta -
ging system18.
BMI was calculated as weight (kg) divided by height
(m2). The subjects were classified according to the
World Health Organization criteria19 as undernou -
rished (BMI < 18.5 kg/m2), well nourished (BMI, 18.5-
24.9 kg/m2), and overweight/obese (BMI ≥ 25 kg/m2). 
The PhA was calculated as the ratio between resis-
tance (R) and reactance (Xc), determined using the
Biodynamics 450® bioimpedance analyzer with the
standard protocol. R and Xc were measured directly in
Ohms (Ω) at a single frequency of 50 kHz and 800 µA.
The measurements were performed after at least 4
hours of fasting, with the patient lying in the supine po-
sition with his/her arms and legs extended to approxi-
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mately 45° from the body. All procedures and controls
for other variables affecting the validity, reproducibili-
ty, and precision of the measurements were performed
according to the National Institutes of Health guide-
lines.20 The PhA was calculated using the following
equation: PhA = arctan (Xc/R) × (180/3.14). 
The validated Portuguese version of the scored PG-
SGA was used to assess nutritional status21. PG-SGA
consists of two sections: in the first, information on
weight history, food intake, nutrition impact symp-
toms, and functional capacity is collected, and in the
second section, diagnosis, disease stage, age, compo-
nents of metabolic demand (sepsis, neutropenic or tu-
mor fever, corticosteroids), and physical examination
were provided by the nutritionist. This analysis classi-
fied patients into three categories: (A) well-nourished,
(B) moderately undernourished or suspected of being
undernourished, and (C) severely undernourished. 
Adipocytokine assays
Blood samples were collected in the morning in the
fasting state. The serum samples were clotted and cen-
trifuged at 2000  × g for 10 minutes and immediately
frozen at –80° C for further analysis. Adipocytokine
levels were measured using enzyme-linked im-
munosorbent assay (ELISA) kit (R&D Systems, MN,
USA), adiponectin levels (with the sample diluted
4,000-fold) using the Duoset ELISA kit (DY1065), and
TNF-α  using the Quantikine ELISA kit (HSTA00D).
The analytical methodology and technical procedures
were performed according to the manufacturer’s proto-
col.
Statistical analysis
The sample size had been calculated, considering the
incidence of CCR in Brazil and the number of new ca -
ses in our Hospital.
Data are presented as percentages or mean ± SD.
Differences between frequencies were assessed by chi-
square test. Student’s unpaired t-test and ANOVA test
were used for normally distributed variables. Appro-
priate nonparametric tests (Mann Whitney U-test and
Kruskal-Wallis test) were employed for all the other
variables. The sample has been considered nonpara-
metric for the study of adiponectin and TNF-alfa serum
levels for the control and cancer group.
For the evaluation of PhA, a cutoff value was esta -
blished for the population studied because of the lack
of specific values for cancer patients. The PhA was di-
vided by the distribution measured according to the
proportion of observed frequencies for both groups.
The data were separated into tertiles and values of the
first tertile were defined as predictors of undernutri-
tion. The analysis of variance was used to compare the
classification of these tertiles for each group. 
SPSS 20.0 (SPSS, Inc., Chicago, IL, USA) was used
for statistical analysis, and values of p < 0.05 were con-
sidered statistically significant.
Results
There was no statistically significant difference with
respect to gender, age and BMI between the groups.
The majority of CRC patients had stage IV tumors
(53.8%); 51.3% were not treated, 46.2% were under -
going chemotherapy, and 41% had undergone surgery
for tumor resection (table I). 
The mean serum levels of adiponectin were higher in
CRC patients (p = 0.001) while TNF-α serum levels
were similar between the groups (p = 0.259). Tumor
stages I and II were analyzed together due to the small
proportion of patients with stage I tumors. Compared
to patients with stages I and II tumor, those with stage
III or IV tumors had higher levels of TNF-α (p = 0.037)
(table II).
The prevalence of moderate or severe undernutri-
tion, as determined using the PG-SGA, was 69.2% in
the case group. Only 7.7% of the CRC patients were
undernourished as per their BMI, and none of the con-
trol group individuals were undernourished. No signi -
ficant differences were found between the groups on
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Table I
Characteristics of the patients in both groups
Parameters Case group Control group p
Age (yr ± SD) 61.0 ± 10.6 60.4 ± 9.2 0.765
Gender Male 25 (64.1) 26 (65) 0.879
N (%) Female 14 (35.9) 14 (35)
Stage I 2 (5.2)
N (%) II 5 (12.8)
III 11 (28.2)
IV 21 (53.8)
BMI (mean ± SD) 23.9 ± 3.3 23.9 ± 2.4 0.893
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the basis of PhA, although more subjects in the case
group were in the first tertile (table III).
The mean of adiponectin (p = 0.337) and TNF-α (p =
0.128) levels was higher in undernourished cancer pa-
tients than in the other subjects; however, these diffe -
rences were not significant. Difference on adiponectin
level was observed between the groups according to
the BMI classification only among the normal weight
subjects (p = 0.009) (table IV). 
The mean serum level of adiponectin (p = 0.073) and
TNF-α (p = 0.005) in the case group was higher among
patients in the first tertile of PhA; however, these dif-
ferences were significant only TNF-α (table V). 
Furthermore, based on the PG-SGA, there was no
difference in adipocytokine levels between groups,
even with the higher number of patients judged to be
moderately or severely undernourished by this method
(table VI).
The influence of nutritional status and
disease on adiponectin and TNF-α levels
in colorectal cancer patients
143Nutr Hosp. 2014;30(1):140-146
Table II
Adiponectin and TNF-α segum levels among the groups and mean values according to the stage of disease for case group
Case group Control group STAGE I and II STAGE III and IV
Adipocytokine (mean ± SD) (mean ± SD) p* mean ± SD mean ± SD p*
Adiponectin (µg/mL) 4.6 ± 2.1 3.6 ± 2.5 0.001 3.9 ± 1.1 4.8 ± 2.3 0.314
TNF-α (pg/mL) 3.7 ± 7.3 3.6 ± 5.1 0.259 1.2 ± 0.7 4.2 ± 7.9 0.037
* Mann Whitney.
Table III
Nutritional assessment results: BMI categories, Patient-Generated Subjective Global Assessment (PG-SGA) categories
and phase angle in both groups
Parameters Case group Control group p
BMI (kg/m2) N (%) N (%) 0.062
Undernourished (<18.5 kg/m2) 3 (7.7) 0 (0)
Normal weight (18.5-24.9 kg/m2) 21 (53.8) 30 (75.0)
Overweight/Obesity ( ≥ 25 kg/m2) 15 (38.5) 10 (25.0)
PG – SGA N (%)
Severely Undernourished 3 (7.7)
Moderately Undernourished 24 (61.5)
Well Nourished 12 (30.8)
Phase Angle Mean ± SD (N)
First tertile 5.1 ± 0.6 (n = 20) 6.0 ± 0.4 (n = 5) 0.161
Second tertile 6.4 ± 0.3 (n = 11) 6.8 ± 0.1 (n = 15) 0.294
Thirth tertile 7.6 ± 0.4 (n = 8) 7.8 ± 0.6 (n = 20) 0.794
Table IV
Adiponectin and TNF-α serum levels in both groups according to the BMI classification
Case group Control group
BMI mean ± SD mean ± SD p*
Undernourished  (<18.5 kg/m2) Adiponectin 6.4 ± 1.7 (n = 3)
TNF-α 9.8 ± 14.8 (n = 3)
Normal weight (18.5-24.9 kg/m2) Adiponectin 4.3 ± 1.3 (n = 21) 3.6 ± 2.7 (n = 30) 0.009
TNF-α 2.3 ± 1.8 (n = 21) 4.1 ± 5.8 (n = 30) 0.559
Overweight/Obesity (BMI ≥ 25 kg/m2)** Adiponectin 4.8 ± 2.9 (n = 15) 3.4 ± 1.7 (n = 10) 0.292
TNF-α 4.4 ± 9.8 (n = 15) 2.2 ± 1.9 (n = 10) 0.375
**The maximum value observed was 32,8 kg/m2 in Case Group and 29,5 kg/m2 in Control Group.
* Mann Whitney.
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Discussion
To our knowledge, this is the first study to investi-
gate the relationship between nutritional status deter-
mined using 3 different parameters (BMI, PhA, and
PG-SGA) and serum levels of adiponectin and TNF-α
in CRC patients. Among the CRC patients, the
adipocytokine levels were also compared with the cli -
nical stage.
We found that patients in the case group had higher
serum levels of adiponectin. When compared to BMI,
this difference was observed in patients with normal
weight. Gonullu et al22, in contrast, reported a lower
level of adiponectin in CRC patients than in a control
group (5.5 ± 5.2 µg/mL vs 6.2 ± 3.0 µg/mL, p = 0.030),
although these groups exhibited no overall difference
in BMI. These differences among the studies might re-
flect a higher proportion of undernourished individuals
in the case group included in our study, and the inclu-
sion of individuals with morbid obesity in the study of
Gonullu et al.22
Adiponectin serum levels are inversely correlated
with body weight in non-cancer patients, with low le -
vels commonly observed in obese subjects7,8. Hillen-
brand et al8 found lower levels of adiponectin in obese
patients without cancer, compared to those with CRC.
Low adiponectin levels have also been described in ad-
vanced lung cancer patients with severe weight loss9.
However, this correlation between weight loss in pa-
tients with lung or intestine cancer and adiponectin le -
vels described by these authors8,9 was not confirmed in
a further independent study17. In our study, the
adiponectin levels were higher in malnourished CRC
patients, as classified by BMI, compared to those with
a BMI ≥ 18.5 mg/m2, but this difference was not statis-
tically significant. The means were not compared for
different categories within the control group because
there were no undernourished control subjects. The dif-
ferent findings of our study and some previously pu -
blished studies might be due to the different nutritional
status of the enrolled patients. 
We also found that patients with a stage III or IV tu-
mor had higher serum adiponectin levels than patients
with stage I and II tumors, although this difference was
not significant. Gonollu el al 22 found higher serum le -
vels of this adipokine in stage II cancer patients than in
those with stage IV tumors (7.58 ± 5.0 µg/mL vs 1.92 ±
2.09 µg/mL). In contrast, Kumor et al6 did not find an
association between the serum concentration of
adiponectin and the clinical stage.
TNF-α is considered an important promoter of va -
rious cytokines, and it has a known role in chronic in-
flammation, angiogenesis, tissue remodeling, tumor
growth, and metastasis23,24. Paradoxically, this cytokine
may also have a pro-apoptotic action, promote inhibi-
tion of tumor angiogenesis, and activate anti-tumor im-
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Table V
Adiponectin and TNF-α serum levels and percentiles of PhA in both groups
Case group Control group
PhA mean ± SD mean ± SD p*
First tertile Adiponectin 5.2 ± 2.5 (n = 20) 6.2 ± 5.5 (n = 5) 0.634
TNF-α 5.9 ± 9.7 (n = 20) 3.5 ± 4.1 (n = 5) 0.812
Second tertile Adiponectin 4.10 ± 1.1 (n = 11) 3.26 ± 2.0 (n = 15) 0.411
TNF-α 1.3 ± 0.7 (n = 11) 5.1 ± 7.5 (n = 15) 0.055
Third tertile Adiponectin 3.9 ± 1.8 (n = 8) 2.9 ± 1.2 (n = 20) 0.172
TNF-α 1.2 ± 0.7 (n = 8) 2.6 ± 2.6 (n = 20) 0.036
* Mann Whitney.
Table VI
Adiponectin and TNF-α according to the PG-SGA in case group
Case group
PG-SGA mean ± SD p*
Well nourished Adiponectin 4.9 ± 3.3 (n = 12) 0.762
Moderately undernourished Adiponectin 4.4 ± 1.2 (n = 24)
Severely undernourished Adiponectin 5.3 ±  2.7 (n = 3)
Well nourished TNF-α 4.4 ± 10.8 (n = 12) 0.225
Moderately undernourished TNF-α 2.4 ± 2.4 (n = 24)
Severely undernourished TNF-α 10.3 ± 14.5 (n = 3)
*Kruskal-Wallis.
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munity4. Studies have shown that excess TNF-α can
cause organ dysfunction and progression of cancer, in-
cluding gastrointestinal tumors.4,25,26 TNF-α increases
lipolysis in adipocytes and consequently, the levels of
circulating free fatty acids.27 An overweight condition
represents an expansion of the adipose tissue with an
increased production of inflammatory factors and cy-
tokines, especially TNF-α, which plays an important
role in the pathophysiology of obesity.4,26 In this study,
we found no significant difference in serum TNF-α
levels between the groups, in agreement with the fin -
dings of a previous study28, although Guadagni et al29
found higher serum levels of TNF-α in cancer patients. 
We also found that serum values of TNF-α were high-
er among patients with advanced disease (stage III and
IV). These findings were similar to those described by
Guadagni et al29, who also found higher TNF-α le vels in
patients with metastatic CRC. These results confirm that
TNF-α may be involved in cancer progression.8 In find-
ings similar to those for adiponectin, TNF-α serum lev-
els in malnourished CRC patients were also higher, al-
though not significantly higher, than those in the
non-cancer controls. Similarly, Hillenbrand et al8 found
a slight but not statistically significant elevation of TNF-
α in CRC patients with a median BMI ≤ 27.1 kg/m2 com-
pared to obese or healthy controls.
In addition to the BMI, adipokine levels also asso -
ciated with PhA and PG-SGA. PhA has been shown to
provide a good estimate of the body compartment and
can be used as a nutritional marker30,31. The levels of
adiponectin and TNF-α with respect to different ter-
tiles showed that the cancer patients in the first tertile
had higher levels of adiponectin, however only TNF-α
levels were significant. Similar findings were observed
in relation to BMI, whereby malnourished patients had
higher levels of adipokines; however, these differences
were not statistically significant. These results suggest
that worse nutritional status may cause higher levels of
adiponectin and TNF-α.
A recent study in our institution using PG-SGA
found that this was the method with a higher sensibility
for determining nutritional status in CRC patients32.
However when analyzed the PG-SGA classification
with adipocytokines, no differences were observed
among the groups, although these adipocytokines in
undernourished patients was higher than in well nou -
rished. Correia et al33 reported that gastric cancer pa-
tients with TNF-α serum levels in excess of 8.72
pg/mL had a higher risk of malnutrition, according to
the PG-SGA. 
This study has some limitations, including the small
number of CRC patients and the inclusion of under-
weight subjects in the case group. Although the control
group consisted of individuals without cancer or gas-
trointestinal disease, the mean age of these subjects,
matching that of the case group, may have favored the
inclusion of individuals with inflammatory conditions,
such as atherosclerosis and type II diabetes, which can
also affect the serum levels of adipokines. The diffe -
rences between serum levels of adiponectin and TNF-α
in some studies may be a consequence of the variation
of this cytokine with clinical stage and body weight.
In summary, the serum level of adipocytokine may
be elevated in CRC patients, and we found that serum
adiponectin levels were higher among CRC patients.
TNF-α serum levels did not differ significantly between
CRC patients and control subjects, but patients with
stage III or IV CRC had higher levels compared to those
with stage I and II tumors. The three measures used to
indicate nutritional status (BMI, PhA, and PG-SGA)
demonstrated that patients with a greater nutritional
deficit had, on an average, higher levels of adipocy-
tokines; however, these differences were not signifi-
cant. Further studies with a greater number of patients
are necessary to fully elucidate the relationship between
adiponectin and TNF-α levels and the nutritional status
and disease stage of CRC patients, and to determinate
the pathophysiological role of adipokines in this cancer.
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